FDA approves InnoPharma’s acetylcysteine inhalation solution

The FDA has approved InnoPharma’s ANDA for acetylcysteine solution. The New Jersey company has a deal with Fresenius Kabi USA to market acetylcysteine solution in the US, where there has been a shortage of the product. Bedford Laboratories recalled acetylcysteine solution earlier this year and American Regent/Luitpold has experienced recurring manufacturing problems.

According to the company, it will make acetylcysteine solution, 20% concentration in 30 ml vials, available within a few weeks.

Read the InnoPharma press release.

Share

published on

Featured event:

July 13-July 162026 ISAM Congress, Taipei, Taiwan

September 15-September 18DDL New Researcher Network Summer Event, London, UK

September 16-September 17IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA

September 24-September 25Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK